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Background. The β-lactamase inhibitor relebactam can restore imipenem activity against imipenem-nonsusceptible gram-neg-
ative pathogens. We evaluated imipenem/relebactam for treating imipenem-nonsusceptible infections.
Methods. Randomized, controlled, double-blind, phase 3 trial. Hospitalized patients with hospital-acquired/ventilator-
associated pneumonia, complicated intraabdominal infection, or complicated urinary tract infection caused by imipenem-
nonsusceptible (but colistin- and imipenem/relebactam-susceptible) pathogens were randomized 2:1 to 5–21 days imipenem/
relebactam or colistin+imipenem. Primary endpoint: favorable overall response (defined by relevant endpoints for each infection 
type) in the modified microbiologic intent-to-treat (mMITT) population (qualifying baseline pathogen and ≥1 dose study treat-
ment). Secondary endpoints: clinical response, all-cause mortality, and treatment-emergent nephrotoxicity. Safety analyses included 
patients with ≥1 dose study treatment. 
Results. Thirty-one patients received imipenem/relebactam and 16 colistin+imipenem. Among mITT patients (n = 21 
imipenem/relebactam, n = 10 colistin+imipenem), 29% had Acute Physiology and Chronic Health Evaluation II scores >15, 23% 
had creatinine clearance <60 mL/min, and 35% were aged ≥65 years. Qualifying baseline pathogens: Pseudomonas aeruginosa (77%), 
Klebsiella spp. (16%), other Enterobacteriaceae (6%). Favorable overall response was observed in 71% imipenem/relebactam and 
70% colistin+imipenem patients (90% confidence interval [CI] for difference, –27.5, 21.4), day 28 favorable clinical response in 71% 
and 40% (90% CI, 1.3, 51.5), and 28-day mortality in 10% and 30% (90% CI, –46.4, 6.7), respectively. Serious adverse events (AEs) 
occurred in 10% of imipenem/relebactam and 31% of colistin+imipenem patients, drug-related AEs in 16% and 31% (no drug-
related deaths), and treatment-emergent nephrotoxicity in 10% and 56% (P = .002), respectively.
Conclusions. Imipenem/relebactam is an efficacious and well-tolerated treatment option for carbapenem-nonsusceptible 
infections.
clinical Trials Registration. NCT02452047.
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Multidrug-resistant (MDR) gram-negative pathogens are en-
demic worldwide [1] and cause infections associated with high 
mortality and morbidity [1–4]. In patients at high risk for poor 
treatment outcomes (eg, immunocompromised or critically ill), 
appropriate antibacterial therapy must be initiated promptly 
to improve survival [5]. Carbapenems are a treatment main-
stay in high-risk patients, and carbapenem-resistant pathogens 
are among the highest-level bacterial threats [2, 4]. To over-
come resistance, carbapenems can be combined with suitable 
β-lactamase inhibitors (BLIs).
Relebactam is a novel non–β-lactam, small-molecule BLI 
that inhibits class A carbapenemases (eg, Klebsiella pneumoniae 
carbapenemase [KPC]) and class C cephalosporinases (eg, 
AmpC) [6], 2 β-lactamases that are frequently involved 
in carbapenem nonsusceptibility. Relebactam is suitable 
for combination with the well-established carbapenem 
imipenem/cilastatin (IMI): inhibiting AmpC frequently 
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restores Pseudomonas aeruginosa susceptibility to imipenem 
but not other carbapenems, neither agent is subject to efflux in 
P. aeruginosa, and their pharmacokinetic/pharmacodynamic 
profiles complement each other [7, 8]. Combining relebactam 
with IMI (IMI/REL) can restore IMI activity against many 
imipenem-nonsusceptible gram-negative pathogens, in-
cluding extended-spectrum β-lactamase (ESBL)-, AmpC-, 
and KPC-producing Enterobacteriaceae [9, 10]. Two phase 2 
trials found IMI/REL safe and no less effective than IMI for 
complicated intraabdominal and urinary tract infections [11, 
12]. Pharmacokinetic/pharmacodynamic analyses [11, 13] 
confirmed 500 mg IMI plus 250 mg REL as the optimum  IMI/
REL dose for further clinical evaluation.
We conducted a randomized, controlled, double-blind 
trial to compare IMI/REL with colistin-based therapy for 
imipenem-nonsusceptible, serious, gram-negative bacterial 
infections. This was a noninferential, descriptive study in-
tended to generate clinical data in this medically important 
patient population as part of a streamlined drug develop-
ment program.
METHODS
Study Design
RESTORE-IMI 1 (protocol MK-7655A-013) was a phase 3, ran-
domized, double-blind study to evaluate the efficacy and safety 
of IMI/REL vs colistin+IMI for imipenem-nonsusceptible in-
fections at 35 hospitals (17 countries). The study was conducted 
in accordance with principles of Good Clinical Practice and 
was approved by the appropriate institutional review boards 
and regulatory agencies. The study protocol is available in the 
Supplementary Materials.
Patients
Eligible patients were aged ≥18 years, hospitalized, and re-
quired intravenous antibacterial treatment for hospital-
acquired pneumonia (HAP)/ventilator-associated pneumonia 
(VAP), complicated urinary tract infections (cUTIs), or compli-
cated intraabdominal infections (cIAIs) caused by imipenem-
nonsusceptible, imipenem/relebactam-susceptible, and 
colistin-susceptible pathogens and lacking clinical improve-
ment on any prior therapy. Diagnosis of eligible infections was 
based on standard definitions (Supplementary Materials).
Patients were eligible based on local prescreening sus-
ceptibility testing: each site tested all gram-negative iso-
lates from urine, intraabdominal, and lower respiratory 
tract samples for susceptibility to the 3 study drugs (Figure 
1).  Broth microdilution testing using Sensititre panels 
(ThermoFisherScientific, Waltham, MA) standardized across 
sites was used to test the samples. Susceptibility was interpreted 
according to each site’s applicable guidelines (either the Clinical 
and Laboratory Standards Institute or the European Committee 
on Antimicrobial Susceptibility Testing) and confirmed for each 
isolate at a central laboratory, using the respective site’s inter-
pretative guideline [14, 15]. Intermediate-susceptible pathogens 
were regarded as nonsusceptible. Imipenem breakpoints were 
applied to imipenem/relebactam. Once patients with eligible 
pathogens were identified, investigators decided whether to 
enter these patients into the formal screening process in order 
to assess other eligibility criteria (Supplementary Materials).
Important exclusion criteria were Acute Physiology and 
Chronic Health Evaluation II (APACHE II) score >30; creat-
inine clearance (CrCL) <15 mL/min; requiring hemodialysis/
peritoneal dialysis; concomitant systemic/inhaled agents active 
Figure 1. Prescreening for gram-negative isolates nonsusceptible to imipenem but susceptible to both imipenem/relebactam and colistin. aFrom specimen types of interest, 
including blood, urinary, intraabdominal, or lower respiratory sources. If information on infection-site specimen source was not available, all gram-negative bacteria were to 
be tested. Abbreviations: GNB, gram-negative bacteria; MIC, minimum inhibitory concentration; SOP, standard operating procedure.
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against Enterobacteriaceae (new taxonomy: Enterobacterales), 
Pseudomonas spp., and gram-negative anaerobic bacilli; prior 
colistin-based therapy; pulmonary obstructions (eg, lung 
cancer) in HAP/VAP; and complete obstruction of any portion 
of the urinary tract in cUTI (Supplementary Materials).
Randomization and Masking
Eligible patients were randomized (stratified by infection type) via 
a centralized, interactive, voice-integrated web response system 
2:1 to intravenous IMI/REL (500 mg/250 mg every 6 hours) plus 
colistimethate sodium placebo or intravenous colistimethate so-
dium (loading dose to achieve 300 mg colistin base activity, fol-
lowed by maintenance doses up to 150 mg colistin base activity, 
every 12 hours), hereafter referred to as colistin, plus IMI (500 
mg every 6 hours). Patients and all investigational staff (except 
pharmacists who prepared infusions) remained blinded to treat-
ment assignments throughout the study. The unblinded study 
pharmacist masked infusion bags with opaque sleeves.
Procedures
IMI/REL, IMI, and colistin doses were adjusted based on renal 
function (Supplementary Materials) and administered over 30 
± 5 minutes. Minimum treatment duration was 5 days (cIAI, 
cUTI) or 7 days (HAP/VAP), with a 21-day maximum. Patients 
were screened for eligibility ≤24 hours before randomization 
(Figure 2). Study visits were performed on day 1 (randomiza-
tion), day 3 (on-therapy visit [OTX]), and at the end of therapy 
(EOT). Following study therapy completion, patients were 
evaluated at an early follow-up visit (EFU) 5–9 days post-EOT 
and on day 28 (could have occurred on the same day as EFU). 
Clinical signs and symptoms were assessed daily during therapy 
and at EOT, EFU, and day 28. In HAP/VAP, chest X rays were 
obtained on day 1 and at EOT.
Infection site cultures (aerobic for all specimens plus an-
aerobic for intraabdominal specimens) for prescreening sus-
ceptibility testing at the local laboratory were collected ≤1 
week before randomization. In cUTI, additional cultures 
were obtained at OTX, EOT, and EFU, and in HAP/VAP or 
cIAI whenever there was evidence of persistent/progressive 
infection or the patient underwent surgical/drainage proced-
ures. Blood cultures were to be collected on day 1 and, if 
positive, repeated until 2 consecutive negative cultures were 
achieved.
Adverse events (AEs) were collected from the first dose 
through 14 days following completion of study therapy. A full 
assessment schedule, including laboratory evaluations, is pro-
vided in the Supplementary Materials.
Outcomes
The microbiologic modified intent-to-treat population 
(mMITT), which was the primary efficacy population, com-
prised all randomized patients with ≥1 dose of study treat-
ment and cultures (collected within 1 week of enrollment) 
confirming ≥1 qualifying (according to central laboratory re-
sults) gram-negative pathogen from the primary infection site. 
The safety population comprised all randomized patients with 
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Figure 2. Assessment schedule. aPatients in these treatment groups had bacterial infections that were imipenem-nonsusceptible but susceptible to imipenem plus relebactam as 
well as to colistin. b≤24 hours prior to randomization. c≤24 hours after the last dose of IV study therapy. Minimum duration of IV therapy was 5 full days for complicated intraabdominal 
infections and complicated urinary tract infections and 7 full days for hospital-acquired pneumonia/ventilator-associated pneumonia. Maximum duration could not exceed 21 days 
without study sponsor approval. d5 to 9 days (up to an additional 2 days) following the end of therapy. e28 days (up to an additional 3 days) following randomization. fIf the day 28 
visit occurred prior to 14 days after the end of therapy, an additional safety follow-up visit was required. Abbreviations: AE, adverse event; day 28, day 28 postrandomization; EFU, 
early follow-up; EOT, end of therapy; IMI, imipenem/cilastatin; IMI/REL, imipenem/cilastatin plus relebactam; IV, intravenous; OTX, on therapy.
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≥1 dose of study treatment according to the actual treatment 
received.
The primary efficacy endpoint was overall response in the 
mMITT population. Overall response was assessed centrally 
and defined differently for each infection type based on reg-
ulatory guidance as follows: HAP/VAP, 28-day all-cause mor-
tality [16]; cIAI, day 28 clinical response [17]; and cUTI, 
composite clinical and microbiologic response at EFU [18]. 
Favorable clinical response was defined as resolution of base-
line signs and symptoms and favorable microbiologic re-
sponse was defined as eradication of baseline uropathogens; 
patients who died or had missing data were considered treat-
ment failures. AE incidence in the safety population was an-
other primary endpoint. Secondary endpoints were day 28 
clinical response (mMITT population), 28-day all-cause mor-
tality (mMITT population), and treatment-emergent nephro-
toxicity (safety population). In patients with normal baseline 
renal function (serum creatinine <1.2 mg/dL), nephrotoxicity 
was defined as serum creatinine doubling (to >1.2 mg/dL) or 
≥50% CrCL reduction. In patients with preexisting renal dys-
function (serum creatinine ≥1.2 mg/dL), nephrotoxicity was 
defined as serum creatinine increases ≥1 mg/dL, ≥20% CrCL 
reduction, or need for renal replacement therapy. All random-
ized, including mMITT, patients were treated and followed up 
identically.
Statistical Analyses
This was an estimation trial without formal statistical testing 
for efficacy endpoints. Within-group 95% confidence inter-
vals (CIs) were calculated using the Agresti and Coull method. 
Between-group differences were calculated using the Miettinen 
and Nurminen method using 90% CIs and stratified by infec-
tion type where appropriate. Treatment-emergent nephrotox-
icity rates were prospectively compared using the 2-sided P 
value from the Fisher exact test. Other safety data were ana-
lyzed using a tiered classification (Supplementary Materials). 
Sample size was based on logistical feasibility, not statistical 
considerations. Randomization of approximately 54 patients 
was planned, with the goal of obtaining approximately 45 parti-
cipants (approximately 15 per infection type) who met mMITT 
inclusion criteria.
RESULTS
Sixteen sites from 11 countries (Supplementary Materials) en-
rolled patients between October 2015 and September 2017. All 
randomized patients (31 IMI/REL, 16 colistin+IMI) received ≥1 
dose of assigned study treatment. The mMITT population com-
prised 31 patients (Figure 3): 11 HAP/VAP, 16 cUTI, and 4 cIAI. 
Baseline demographic, clinical, and microbiologic characteris-
tics were similar between treatment arms (Table 1). Notably, 
29% of mMITT patients had APACHE-II scores >15 (higher in 
HAP/VAP and cIAI than cUTI), 23% had CrCL <60 mL/min, 
and 35% were aged ≥65 years. Prior antibacterial therapies were 
largely comparable between arms, but prior meropenem was 
more frequent in IMI/REL patients (Supplementary Materials).
Qualifying baseline pathogens in mMITT patients, mostly 
(65%) from cultures obtained ≤3 days before randomization 
(Supplementary Materials), were P. aeruginosa (77%), Klebsiella 
spp. (16%), and other Enterobacteriaceae (6%). All patients 
with HAP/VAP and cIAI had P. aeruginosa, except 1 with cIAI 
due to Citrobacter freundii. Patients with cUTI also mostly had 
P. aeruginosa, along with Klebsiella spp. and Enterobacter spp. 
(Supplementary Materials). Detected β-lactamases included 
AmpC (84% of mMITT patients), ESBLs (35%), KPC (16%), 
and OXA-48 (3%) (Supplementary Materials). Minimum in-
hibitory concentrations (MICs) for study drugs are listed in the 
Supplementary Materials. Resistance rates to most nonstudy 
antibacterial agents were high (Supplementary Materials). In 
the mMITT population, mean (range) treatment duration 
was 11.4 (2–18) days with IMI/REL and 10.8 (2–20) days with 
colistin+IMI; median treatment duration was 12.5 days and 9.8 
days, respectively. Treatment compliance was 100%.
Most mMITT patients achieved a favorable overall response 
(IMI/REL, 71%; colistin+IMI, 70%; difference, –7.3%; 90% CI, 
–27.5%, 21.4%; Table 2). In both arms, most patients with HAP/
VAP and cUTI, but none with cIAI, achieved favorable overall 
response (Table 2). Among cIAI patients, 1 out of 2 in both arms 
had unfavorable overall responses because of missing/indeter-
minate data.
Favorable overall response against P. aeruginosa was observed 
in 13/16 (81%) of IMI/REL and 5/8 (63%) of colistin+IMI pa-
tients; against Enterobacteriaceae, response rates were 2/5 
(40%) and 2/2 (100%), respectively (Supplementary Materials). 
Of the 3 patients with Enterobacteriaceae and unfavorable 
overall response, 1 had cIAI due to C. freundii and 2 cUTI due 
to K. pneumoniae. The patient with C. freundii (carrying KPC-
2, a plasmid-borne AmpC, and TEM-1 β-lactamases) was a 
59-year-old male with a complex medical history (recurrent 
rectal carcinoma, small bowel resection, pleural effusions, and 
emphysema) who died on day 3 due to pneumonia (cIAI not 
deemed contributory). Both patients with K. pneumoniae (1 
carrying KPC-2, 3 different ESBLs, and TEM-1 and the other 
carrying KPC-3, SHV-11, and TEM-1) had favorable clinical 
and microbiologic responses at EOT but recurrence at EFU. 
Neither patient had clinical signs or symptoms associated with 
the recurring pathogen; these 2 were the only cUTI patients 
with chronic intermittent urinary catheterization, which likely 
contributed to recurrence. Of the 2 patients with confirmed 
baseline bacteremia (despite being protocol-required, baseline 
blood cultures were available for only 9 patients), 0/1 receiving 
IMI/REL and 1/1 receiving colistin+IMI had favorable overall 
response. Prior meropenem therapy did not impact overall 
response (Supplementary Materials). Patients with baseline 
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qualifying cultures obtained >3 days before randomization did 
not have better outcomes than those with cultures collected ≤3 
days before; favorable overall response rates were 5/11 (45%) 
and 17/20 (85%), respectively.
Favorable clinical response rates were 31% higher with IMI/
REL than with colistin+IMI at day 28 and were also higher at 
EOT and EFU (Supplementary Materials). Day 28 all-cause 
mortality was 20% lower with IMI/REL (Table 2). All mMITT 
patients with cUTI achieved favorable microbiological re-
sponse at all visits, except 3 of 11 IMI/REL patients at EFU due 
to missing urine cultures (n = 1) and baseline pathogen re-
currence at EFU without changes in susceptibility (n = 2; see 
above). There were no instances of treatment-emergent IMI/
REL nonsusceptibility.
Treatment-emergent nephrotoxicity was significantly less 
frequent (P = .002) with IMI/REL than with colistin+IMI: 3/29 
(10%) vs 9/16 (56%), respectively (95% CI for difference, –69.1%, 
–18.4%). Significantly (P = .047) fewer patients receiving IMI/
REL (0/31, 0%) than colistin+IMI (2/16, 13%) experienced 
clinically relevant elevations in hepatic transaminases, a prede-
fined tier 1 safety parameter. Most patients (71% IMI/REL, 81% 
colistin+IMI) had ≥1 AE (Table 3). Drug-related AEs were re-
ported in 16% of IMI/REL vs 31% of colistin+IMI patients, and 
serious AEs in 10% vs 31%, respectively. There were also fewer 
deaths with IMI/REL (6% vs 19%); no deaths were considered 
drug-related. Three patients (19%) in the colistin+IMI and none 
in the IMI/REL arm discontinued treatment due to AEs (drug-
related blood creatinine increase, drug-related CrCL increase, and 
treatment-emergent infection; n = 1 each). The most common 
AEs were pyrexia (13%), increased aspartate aminotransferase 
(AST; 13%), increased alanine aminotransferase (ALT; 11%), and 
nausea (11%; Table 4, Supplementary Materials). Incidence of py-
rexia was comparable in both groups; increased AST, increased 
ALT, and nausea were less frequent with IMI/REL (Table 4). The 
only IMI/REL drug-related AE in >1 patient was decreased CrCL 
(6%), also reported in 13% of colistin+IMI patients (Table 4).
DISCUSSION
This randomized, controlled, double-blind trial that com-
pared IMI/REL with colistin-based therapy showed that IMI/
REL was effective for treating carbapenem-nonsusceptible 
Microbiologic modified intent-to-treat 
population (N = 21)
Excluded from population (n = 10)
(Pathogen did not meet susceptibility criteria
in central laboratory testing n = 8, qualifying
microbiologic culture collected >1 week
before study entry n = 2)
Not enrolled (N=4)
(Did not meet infection eligibility criteria
n = 2, did not meet pathogen eligibility
criteria n = 1, delayed drug supply n = 1)
Microbiologic modified intent-to-treat 
population (N = 10)
Excluded from population (n = 6)
(Pathogen did not meet susceptibility criteria
in central laboratory testing n = 5, qualifying
microbiologic culture collected >1 week
before study entry n = 1)
Safety population (N = 31)
Prematurely discontinued IV medication (n = 4)
(Physician decision n = 2, treatment failure
n = 1, patient withdrew consent n = 1)
Safety population (N = 16)
Prematurely discontinued IV medication (n = 5)
(Adverse event n = 3, death n = 1, physician
decision n = 1)
IMI/REL (N = 31)
Randomized 2:1 (N = 47)
Screeneda (N = 54)
Colistin + IMI (N = 16)
Allocation
Enrollment
Analysis
Figure 3. Study analysis populations flow chart. aLocal diagnostic laboratories at each investigative site were asked to prescreen all incoming gram-negative isolates 
obtained from infection sites of interest against the sponsor-provided screening panels for resistance to IMI and susceptibility to IMI/REL and colistin. Investigators were 
notified of all isolates that met microbiologic eligibility criteria. Investigators then reviewed the patient’s general information to determine whether to proceed with actual 
screening, that is, based on protocol-specified procedures. Many patients with eligible isolates did not enter the formal screening process if, for example, the investigator 
was able to readily determine that a patient did not meet a major entry criterion. Screening was performed after obtaining patient consent. Abbreviations: IMI, imipenem/
cilastatin; IMI/REL, imipenem/cilastatin plus relebactam; IV, intravenous.
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Table 1. Baseline Demographics and Clinical Characteristics in the Modified Microbiologic Intent-to-Treat Population
Baseline characteristic IMI/REL (n = 21) Colistin + IMI (n = 10) Total (n = 31)
Sex    
 Male, n (%) 13 (61.9) 7 (70.0) 20 (64.5)
 Female, n (%) 8 (38.1) 3 (30.0) 11 (35.5)
Age, y    
 <65, n (%) 15 (71.4) 5 (50.0) 20 (64.5)
 ≥65, n (%) 6 (28.6) 5 (50.0) 11 (35.5)
 Median (range) 59 (19–75) 61 (49–80) 59 (19–80)
Weight, kg    
 Median (range) 75 (53.0–132.3) 75.6 (52.8–117.0) 75 (52.8–132.3)
Creatinine clearance (mL/min)    
 ≥90, n (%) 8 (38.1) 3 (30.0) 11 (35.5)
 <90 to ≥60, n (%) 8 (38.1) 4 (40.0) 12 (38.7)
 <60 to ≥30, n (%) 3 (14.3) 2 (20.0) 5 (16.1)
 <30 to ≥15, n (%) 1 (4.8) 1 (10.0) 2 (6.5)
 Not available, n (%) 1 (4.8) 0 (0.0) 1 (3.2)
Acute Physiology and Chronic Health Evaluation II score    
 ≤15, n (%) 14 (66.7) 8 (80.0) 22 (71.0)
 >15, n (%) 7 (33.3) 2 (20.0) 9 (29.0)
 Patients with HAP/VAP, median (range) 16 (0, 26) 22 (14, 23) 18 (0, 26)
 Patients with cIAI, median (range) 18 (17, 19) 14.5 (14, 15) 16 (14, 19)
 Patients with cUTI, median (range) 5 (0, 17) 7 (4, 15) 5.5 (0, 17)
Primary diagnosis    
 HAP, n (%) 1 (4.8) 1 (10.0) 2 (6.5)
 VAP, n (%) 7 (33.3) 2 (20.0) 9 (29.0)
 cUTI (urinary tract abnormalities), n (%) 5 (23.8) 3 (30.0) 8 (25.8)
 cUTI (acute pyelonephritis), n (%) 6 (28.6) 2 (20.0) 8 (25.8)
 cIAI, n (%) 2 (9.5)a 2 (20.0)b 4 (12.9)
Bacteremiac    
 Yes, n (%) 1 (4.8) 1 (10.0) 2 (6.5)
 No, n (%) 5 (23.8) 2 (20.0) 7 (22.6)
 Unknown, n (%)c 15 (71.4) 7 (70.0) 22 (71.0)
Qualifying causative pathogens    
 Citrobacter freundii, n (%) 1 (4.8) 0 (0.0) 1 (3.2)
 Enterobacter cloacae, n (%) 1 (4.8) 0 (0.0) 1 (3.2)
 Klebsiella oxytoca, n (%) 0 (0.0) 1 (10.0) 1 (3.2)
 Klebsiella pneumoniae, n (%) 3 (14.3) 1 (10.0) 4 (12.9)
 Pseudomonas aeruginosa, n (%) 16 (76.2) 8 (80.0) 24 (77.4)
β-lactamasesd    
 Class A    
  Older spectrum β-lactamases    
   SHVe 2 (9.5) 1 (10.0) 3 (9.7)
   TEM 7 (33.3) 3 (30.0) 10 (32.3)
  Extended spectrum β-lactamases    
   CTX-M 7 (33.3) 4 (40.0) 11 (35.5)
   SHVe 1 (4.8) 0 1 (3.2)
   VEB 0 0 0
  Serine carbapenemases    
   KPC 4 (19.0) 1 (10.0) 5 (16.1)
 Class C    
  Chromosomal AmpC    
   PDC 16 (76.2) 8 (80.0) 24 (77.4)
  Plasmid-mediated AmpC    
   ACT 0 0 0
   CMY 1 (4.8) 0 1 (3.2)
   DHA 1 (4.8) 0 1 (3.2)
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz530/5546004 by guest on 27 August 2019
IMI/REL for Carbapenem Resistance • cid 2019:XX (XX XXXX) • 7
gram-negative infections without the nephrotoxicity associ-
ated with colistin. Primary efficacy outcomes were similar be-
tween treatment arms, with favorable overall response in about 
70% of patients. IMI/REL-treated patients had higher clinical 
response rates and lower 28-day mortality than those who re-
ceived colistin-based therapy, but the study was not powered for 
statistical inference. Furthermore, the incidence of treatment-
emergent nephrotoxicity, serious AEs, and drug-related AEs 
was higher with colistin. These results are noteworthy given the 
rigorous study design, that is, a carefully blinded evaluation of 
IMI/REL vs a dose-optimized, single-comparator regimen.
The study population comprised patients at high risk for poor 
outcomes, including death. In addition to having confirmed 
MDR, often severe infections, many participants also had high 
APACHE II scores, renal insufficiency or other comorbidities, 
substantial clinical complexity, extensive pretrial antibacterial 
therapy, or were elderly. Treatment groups were well-balanced 
at baseline. The pathogen distribution aligned with previous 
reports that suggested that carbapenem resistance is more 
common in Pseudomonas than in Enterobacteriaceae [3, 9, 19, 
20]. Prior treatments, except meropenem, also appeared compa-
rable. There were no trends in outcomes with prior meropenem. 
Of note, eligible patients had to be failing any prior therapy and 
have imipenem-nonsusceptible pathogens, reflected in the high 
cross-resistance of baseline pathogens to commonly used first-
line therapies. High-risk patients, especially those potentially 
(due to local/institutional epidemiology and/or presence of risk 
factors) or definitively affected by carbapenem-resistant patho-
gens, should rapidly receive appropriate therapy to improve sur-
vival and shorten hospital length of stay [5]. Colistin is widely 
included in guidelines for treating carbapenem-resistant patho-
gens [21–25], despite being associated with dose-dependent 
nephrotoxicity and neurotoxicity [26]. Poor clinical outcomes 
and resistance emergence, worsened by inadequate dosing 
strategies, are also frequent concerns with colistin [1]. Recent 
guidelines recommend colistin-based combination therapy, 
including with carbapenems, over colistin monotherapy when 
treating carbapenem-resistant Enterobacteriaceae (CRE) and P. 
aeruginosa infections [21, 25, 27].
Given colistin’s role in treating carbapenem-resistant infec-
tions, its use as a comparator in several similar clinical trials, 
and its potential synergy with carbapenems, we chose the com-
bination of colistin with IMI as the active comparator [21, 25, 
27]. This choice also enabled the double-blind study design and 
a straightforward comparison of REL and colistin, since all pa-
tients received identical β-lactam background therapy. IMI is 
an optimal partner carbapenem for REL since REL’s pharma-
cokinetic/pharmacodynamic profile, including renal elimi-
nation and interaction with various resistance mechanisms, 
complements that of IMI [7, 8]. In combination with 250 mg 
REL, standard-dose (500 mg) IMI appears effective even against 
highly resistant pathogens [11, 13].
The combination of IMI with REL can overcome many 
gram-negative resistance mechanisms (including β-lactamase 
production/overexpression, porin loss, and efflux) [19, 20, 28–
31] and is active against most strains of KPC producers, ESBL 
producers, and MDR/carbapenem-resistant Pseudomonas 
but not metallo-β-lactamases (eg, NDM) and/or class D 
β-lactamases (eg, OXA-48). REL generally does not improve 
imipenem susceptibility in Acinetobacter baumannii [6]. IMI/
REL is a potential monotherapy agent, with coverage of many 
gram-positive and anaerobic pathogens [7, 10].
The RESTORE-IMI 1 trial was unique for several reasons. 
Data were generated specifically in the target population of in-
terest (patients with carbapenem-nonsusceptible infections). 
The double-blinded study design allowed for robust assessment 
of IMI/REL safety and efficacy, and limiting comparator treat-
ment to a single regimen rather than “best available therapy” 
reduced variability and ensured that all patients received ap-
propriate therapy (only patients with colistin-susceptible infec-
tions were enrolled). Colistin dosing was optimized based on 
contemporary pharmacokinetic/pharmacodynamic modeling 
[32, 33]. Finally, pathogen susceptibility was confirmed rap-
idly through study-agent–specific test panels concurrently with 
each site’s standard, first-line susceptibility testing, allowing 
timely therapy initiation at the same point for all patients (ie, 
once pathogens were confirmed to meet microbiologic eligi-
bility criteria), thus ensuring a rigorous treatment comparison.
Baseline characteristic IMI/REL (n = 21) Colistin + IMI (n = 10) Total (n = 31)
 Class D    
  OXA-48 0 1 (10.0) 1 (3.2)
Abbreviations: cIAI, complicated intraabdominal infection; cUTI, complicated urinary tract infection; HAP, hospital-acquired bacterial pneumonia; IMI, imipenem/cilastatin; IMI/REL, imipenem/
cilastatin plus relebactam; KPC, Klebsiella pneumoniae carbapenemase; VAP, ventilator-associated bacterial pneumonia.
aPerforated colon (n = 1), liver abscess (n = 1). 
bPerforated jejunum/ileum and colon, postsurgical peritonitis (n = 1), intraabdominal abscess (n = 1). 
cBaseline blood cultures were available from only 9 patients in the overall modified microbiologic intent-to-treat population.
dQualifying baseline pathogens could have had multiple β-lactamases detected. Of isolates with class A β-lactamases, all but 3 isolates carried multiple class A β-lactamases. A detailed 
breakdown by pathogen is provided in the Supplementary Materials. 
eOlder spectrum β-lactamases were SHV-1 and SHV-11. Extended spectrum β-lactamase was SHV-28.
Table 1. Continued
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This study had several limitations, including the small 
sample size. Under certain circumstances, for example, when 
the parent drug of a BL/BLI combination has established safety 
and efficacy, regulatory agencies allow streamlined drug de-
velopment programs for antibacterials that target unmet med-
ical need. These programs aim to generate limited clinical data 
in the target population, supplemented with preclinical and 
pharmacokinetic/pharmacodynamic studies and the parent 
compound’s existing safety and efficacy data. Streamlined 
development programs acknowledge that large noninferiority 
trials in MDR infections are not feasible. Patients must meet 
regulatory definitions for the specific infection types included, 
be ill enough to require salvage therapy but not too ill to par-
ticipate and contribute meaningful data, and be hospitalized at 
experienced clinical trial sites. The scarcity of patients with con-
firmed carbapenem-nonsusceptible infections who meet these 
requirements and consent for such trials was reflected in the 
small number of eligible, enrolled participants. Most exclusions 
Table 2. Primary and Secondary Prospective Efficacy Endpoints (in the Modified Microbiologic Intent-to-Treat Population) and Secondary Prospective 
Safety Endpoints (in the Safety Population)
Endpoint
IMI/REL (n = 21) Colistin + IMI (n = 10)
Unadjusted 
Difference Adjusted Differencea
n % (95% CI)b n % (95% CI)a % % 90% CI
Primary endpoint
 Favorable overall responsec 15 71.4 (49.8, 86.4) 7 70.0 (39.2, 89.7) 1.4 –7.3 (–27.5, 21.4)
   Hospital-acquired bacterial pneumonia/ 
ventilator-associated bacterial pneumonia
7/8 87.5 (50.8, 99.9) 2/3 66.7 20.8
  Complicated intraabdominal infection 0/2d 0.0 0/2e 0.0 0.0
  Complicated urinary tract infection 8/11 72.7 (42.9, 90.8) 5/5 100.0 (51.1, 100.0) –27.3 (–52.8, 12.8)
Secondary endpoints
 Favorable clinical response (day 28) 15f 71.4 (49.8, 86.4) 4g 40.0 (16.7, 68.8) 31.4 26.3 (1.3, 51.5)
 28-day all-cause mortality 2 9.5 (1.4, 30.1) 3 30.0 (10.3, 60.8) –20.5 –17.3 (–46.4, 6.7)
 Treatment-emergent nephrotoxicityh 3/29 10.3 (2.8, 27.2) 9/16 56.3 (33.2, 76.9) –45.9 (–69.1, –18.4)
CIs are not presented if the number of patients with assessment was <4.
Abbreviations: CI, confidence interval; IMI, imipenem/cilastatin; IMI/REL, imipenem/cilastatin plus relebactam.
aBased on the Miettinen and Nurminen method stratified by infection site.
bBased on the Agresti and Coull method.
cOverall response defined as hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia (HAP/VAP), survival through day 28; complicated intraabdominal infection 
(cIAI), clinical response at day 28; complicated urinary tract infection (cUTI), composite clinical and microbiological response 5–9 days after the end of therapy (EOT). 
dOne of these patients had cIAI due to Citrobacter freundii encoding Klebsiella pneumoniae carbapenemase KPC-2 and the plasmid-borne AmpC CMY-48; this patient died on day 3 due to 
pneumonia, with the cIAI not deemed contributory to this death (indeterminate overall response). The other patient had cIAI due to Pseudomonas. aeruginosa encoding the chromosomal 
AmpC PDC-30, with persistence at the on-therapy visit (OTX) and failure at EOT, the on-therapy visit (EFU), and day 28 (unfavorable overall response).
eOne of these patients had cIAI due to P. aeruginosa encoding the chromosomal AmpC PDC-1, with indeterminate response at OTX, response of “improved” at EOT, and indeterminate 
response at EFU and day 28 (indeterminate overall response). The other patient had cIAI due to P. aeruginosa isolate encoding the chromosomal AmpC PDC-39, with investigator-assessed 
response of “improved” at OTX, “cure” at EOT, and “sustained cure” at EFU and day 28; based on prospectively defined rules, prior to unblinding the patient was imputed as having had an 
unfavorable overall response due to having received confounding, protocol-prohibited antibacterial therapy. 
fTwo HAP/VAP patients with favorable overall response (ie, alive at day 28) had an unfavorable clinical response at day 28, while 2 cUTI patients had favorable clinical response at day 28 but 
(due to lack of microbiologic response) did not have a favorable overall response. 
gOf 3 patients with favorable overall response (defined differently for each infection type, see footnote “c”) but lack of day 28 favorable clinical response, 1 patient with HAP/VAP experienced 
confirmed clinical failure but was still alive by day 28, 1 patient with HAP/VAP due to P. aeruginosa and Delftia acidovorans had an indeterminate clinical response (ie, extenuating circum-
stances precluded response classification, but the patient still required mechanical ventilation and had hypoxemia) but was still alive by day 28, and 1 patient with cUTI was lost to follow-up 
by day 28 but had favorable composite clinical and microbiological response 5–9 days after EOT. 
hAssessed in evaluable safety population patients (IMI/REL, n = 29; colistin + IMI, n = 16).
Table 3. Summary of Adverse Events During Intravenous Therapy and the 14-Day Follow-up Period in the Safety Population
Patients With AEs IMI/REL (n = 31) Colistin + IMI (n = 16)
Unadjusted Difference  
(95% Confidence Interval)a
At least 1 AE, n (%) 22 (71.0) 13 (81.3) –10.3 (–33.1, 18.0)
Drug-related AEs, n (%) 5 (16.1) 5 (31.3) –15.1 (–42.3, 9.2)
Serious AEs, n (%) 3 (9.7) 5 (31.3) –26.1 (–47.8,1.3)
Serious drug-related AEs, n (%) 0 (0.0) 0 (0.0) 0.0 (–19.7, 11.2)
Deaths, n (%) 2 (6.5) 3 (18.8) –12.3 (–37.8, 6.5)
Drug-related deaths, n (%) 0 (0.0) 0 (0.0) 0.0 (–19.7, 11.2)
Discontinued drug due to AE, n (%) 0 (0.0) 3 (18.8) –18.8 (–43.3, –6.2)
Discontinued drug due to drug-related AE, n (%) 0 (0.0) 2 (12.5) –12.5 (–36.3, –0.3)
Abbreviations: AE, adverse event; IMI, imipenem/cilastatin; IMI/REL, imipenem/cilastatin plus relebactam.
aBased on the Miettinen and Nurminen method.
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from the primary efficacy population were due to differences 
in susceptibility testing between local and central laboratories. 
This was not unexpected since eligibility required susceptibility 
to 3 different agents and repeat test results frequently differ by 1 
or 2 dilutions, which can affect susceptibility interpretation. The 
small sample size was mitigated by the well-established safety 
and efficacy profile of the IMI component of IMI/REL and the 
robust safety, tolerability, and efficacy data from the IMI/REL 
phase 2 program [11, 12]. Few cIAI patients were enrolled, 
largely because there were fewer prescreening isolates from 
intraabdominal than urinary and lower respiratory tract speci-
mens. The lack of favorable response among cIAI patients could 
have been due to their medical complexity, evidenced by exten-
sive pretrial antibacterial therapy and high APACHE II scores. 
Furthermore, 50% of cIAI patients had unfavorable outcomes 
due to indeterminate responses (data missing for any reason 
except cIAI-attributable death). Relatively few patients with 
CRE were enrolled, thus limiting interpretability among this 
subpopulation. Since in vitro susceptibility can be considered a 
reasonable predictor of favorable therapeutic response [34], IMI 
is recommended for treating infections caused by imipenem-
susceptible pathogens (including Enterobacteriaceae) [22–24, 
35].  Relebactam restores in vitro imipenem susceptibility 
against most CRE [6, 9, 10, 13], and IMI/REL can there-
fore be expected to have clinical efficacy against imipenem/
relebactam-susceptible CRE strains. Another limitation is that 
while treatment-emergent nephrotoxicity was protocol-defined 
to apply a consistent, objective definition, alternative definitions 
of kidney injury exist [36].
Our results support IMI/REL as a suitable treatment option 
for serious gram-negative infections, including those caused 
by carbapenem-nonsusceptible pathogens in high-risk pa-
tients. IMI/REL may be preferable to colistin-based therapy 
for treating carbapenem-nonsusceptible infections, given that 
IMI/REL had comparable efficacy but significantly less nephro-
toxicity and other AEs.
Supplementary Data
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